Company intelligence / Profile preview

NextGen Bioscience

Republic of Koreanextgenbio.co.kr ↗
Ownership
Public · NXGN
Employees
~50
Development stage
Other
01

Overview

Clinical stage biotechnology company developing novel small molecule therapeutics for fibrotic diseases

Therapeutic areas
GastroenterologyOphthalmologyPulmonologyDermatology
Modalities
Small molecule therapeutics
Industry
Biotech
02

Drug pipeline

8 assets

vonifimod

2

7 more assets in the full pipeline.

Beyond the preview

Go deeper on NextGen Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NextGen Bioscience.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call